60 Degrees’ Arakoda Gets US FDA Panel Nod For Malaria Prophylaxis

 
• By Sue Sutter

Postmarketing studies are needed to assess tafenoquine’s efficacy in children, older adults and heavier individuals, and to answer questions about psychiatric safety and other adverse events, advisory committee says.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers